Is Dicerna Pharmaceuticals Inc (DRNA) Stock a Smart Investment Monday?
Monday, December 20, 2021 10:30 AM | InvestorsObserver Analysts
Mentioned in this article
Dicerna Pharmaceuticals Inc (DRNA) stock has risen 67.98% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives DRNA stock a score of 66 out of a possible 100.
That rank is primarily influenced by a long-term technical score of 100. DRNA's rank also includes a short-term technical score of 90. The fundamental score for DRNA is 7. In addition to the average rating from Wall Street analysts, DRNA stock has a mean target price of $37.29. This means analysts expect the stock to fall 1.96% over the next 12 months.
DRNA has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on DRNA!
Dicerna Pharmaceuticals Inc (DRNA) stock has risen 0.58% while the S&P 500 is lower by -1.68% as of 10:29 AM on Monday, Dec 20. DRNA has risen $0.22 from the previous closing price of $37.81 on volume of 489,150 shares. Over the past year the S&P 500 has risen 22.96% while DRNA has risen 67.98%. DRNA lost -$1.63 per share in the over the last 12 months.
Click Here to get the full Stock Report for Dicerna Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
